CONFIDENTIAL  Clinical Study Protocol  
No. B AY 1021189  / 21683 
29 NOV 2023   Page:   1 of 44 
 
Title Page  
Protocol Title: A Phase 2b open-label  clinical study to evaluate the toler ability and safety of 
an initiation  dose of 5 mg of Vericiguat  in partic ipants  with chronic heart failure with reduced 
ejection fraction  
Protocol Number:   21683  
Protocol Version:    1.0 
Amendment Number:  Not applicable  
Compound Number:   BAY 1021189 , Vericiguat, Verquvo  
Short  Title :    Vericiguat 5 mg initiation  study  
Study Phase:    2 
Acronym:    VELOCITY  HF 
Sponsor Name:    Bayer AG  
Legal Registered Address:  
Non-US: Bayer AG, 51368 Leverkusen, Germany  
US territory: Bayer HealthCare Pharmaceuticals Inc., 100 Bayer Boulevard, P.O. Box 915, 
Whippany NJ 07981 -0915, USA  
Regulatory Agency Identifier Numbers:    
Registry    ID 
EU CT:     2023 -507682 -25-00 
IND:     116,743   
 
Protocol Date:  29 NOV 2023  
Name:        Role:   
 
This is an electronically generated document that does not bear any sponsor signatures. The 
signature of the sponsor’s medically responsible person i s filed in the TMF and available on 
request.  
 
Medical Monitor name and contact information  can be found in the Trial Master File.   
 
Confidential  
The information provided in this document is strictly confidential and is intended solely for the performance of 
the clinical investigation.  Reproduction or disclosure of this document, whether in part or in full, to parties not 
associated with the clinical investigation or its use for any other purpose without the prior written consent of the 
sponsor is not permitted.  
Throughout this document, symbols indicating proprietary names (®, TM) may not be displayed. Hence, the 
appearance of product names without these symbols does not imply that these names are not protected.  
PPD
PPD
CONFIDENTIAL  Clinical Study Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:  2 of 44 
 
Table of Contents  
Title Page  ................................ ................................ ................................ ...............................  1 
Table of Tables  ................................ ................................ ................................ .....................  4 
Table of Figur es ................................ ................................ ................................ ....................  4 
List of Abbreviations  ................................ ................................ ................................ ............  5 
1. Protocol Summary  ................................ ................................ ................................ ........  7 
1.1 Synopsis  ................................ ................................ ................................ .......................  7 
1.2 Schema  ................................ ................................ ................................ .........................  8 
1.3 Schedule of Activities (SoA)  ................................ ................................ .......................  9 
2. Introduction  ................................ ................................ ................................ .................  10 
2.1 Study Rationale  ................................ ................................ ................................ ..........  10 
2.2 Background  ................................ ................................ ................................ ................  10 
2.3 Benefit/Risk Assessment  ................................ ................................ ...........................  11 
2.3.1  Risk Assessment  ................................ ................................ ................................ ..... 11 
2.3.2  Benefit Assessment  ................................ ................................ ................................  12 
2.3.3  Overall Benefit: Risk Conclusion  ................................ ................................ ...........  12 
3. Objectives, Endpoints  ................................ ................................ ................................ . 13 
4. Study Design  ................................ ................................ ................................ ................  13 
4.1 Overall Design  ................................ ................................ ................................ ...........  13 
4.2 Scientific Rationale for Study Design  ................................ ................................ ....... 13 
4.3 Justification for Dose  ................................ ................................ ................................ . 14 
4.4 End-of-Study Definition  ................................ ................................ ............................  15 
5. Study Population  ................................ ................................ ................................ .........  15 
5.1 Inclusion Criteria  ................................ ................................ ................................ ....... 16 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...... 17 
5.3 Lifestyle Considerations  ................................ ................................ ............................  19 
5.4 Screen Failures  ................................ ................................ ................................ ...........  19 
5.5 Criteria for Temporarily Delaying Study Intervention  ................................ ..............  20 
6. Study Intervention and Concomitant Therapy  ................................ ........................  20 
6.1 Study Intervention Administered  ................................ ................................ ...............  20 
6.2 Preparation, Handling, Storage, and Accountability  ................................ .................  20 
6.3 Assignment to Study Intervention  ................................ ................................ .............  21 
6.4 Blinding  ................................ ................................ ................................ .....................  21 
6.5 Study Intervention Compliance  ................................ ................................ .................  21 
6.6 Dose Modification  ................................ ................................ ................................ ..... 22 
6.6.1  Retreatment Criteria  ................................ ................................ ...............................  22 
6.7 Continued Access to Study Intervention after the End of the Study  .........................  22 
6.8 Treatment of Overdose  ................................ ................................ ..............................  22 
6.9 Prior and Concomitant Therapy  ................................ ................................ .................  22 
6.9.1  Rescue Medicine ................................ ................................ ................................ ..... 23 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  ................................ ................................ ......................  23 
7.1 Discontinuation of Study Intervention  ................................ ................................ ....... 23 
7.1.1  Temporary Interruption  ................................ ................................ ..........................  24 
CONFIDENTIAL  Clinical Study Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:  3 of 44 
 
7.1.2  Rechallenge  ................................ ................................ ................................ ............  24 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ...........  24 
7.3 Lost to Follow Up  ................................ ................................ ................................ ...... 24 
8. Study Assessments and Procedures  ................................ ................................ ...........  25 
8.1 Administrative and Baseline Procedures  ................................ ................................ ... 25 
8.2 Efficacy Assessments  ................................ ................................ ................................  25 
8.3 Safety Assessments  ................................ ................................ ................................ .... 25 
8.3.1  Physical Examinations  ................................ ................................ ............................  25 
8.3.2  Vital Signs  ................................ ................................ ................................ ..............  26 
8.3.3  Electrocardiograms  ................................ ................................ ................................ . 26 
8.3.4  Clinical Safety Laboratory Tests  ................................ ................................ ............  27 
8.3.5  Pregnancy Testing  ................................ ................................ ................................ .. 27 
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs) and Other Safety Reporting
 ................................ ................................ ................................ ................................ ... 27 
8.4.1  Time Period and Frequency for Collecting A E and SAE Information ...................  27 
8.4.2  Method of Detecting AEs and SAEs  ................................ ................................ ...... 28 
8.4.3  Follow -up of AEs and SAEs  ................................ ................................ ..................  28 
8.4.4  Regulatory Reporting Requirements for SAEs  ................................ ......................  28 
8.4.5  Pregnancy  ................................ ................................ ................................ ...............  28 
8.4.6  Adverse Events of Special Interest  ................................ ................................ .........  29 
8.5 Pharmacokinetics  ................................ ................................ ................................ ....... 29 
8.6 Pharmacodynamics  ................................ ................................ ................................ .... 29 
8.7 Genetics  ................................ ................................ ................................ .....................  29 
8.8 Biomarkers  ................................ ................................ ................................ .................  29 
8.9 Immunogeni city Assessments  ................................ ................................ ....................  29 
8.10  Medical Resource Utilization and Health Economics  ................................ ...............  29 
9. Statistical Considerations  ................................ ................................ ...........................  29 
9.1 Statistical Hypotheses  ................................ ................................ ................................  29 
9.1.1  Multiplicity Adjustment  ................................ ................................ .........................  29 
9.2 Analysis Sets  ................................ ................................ ................................ ..............  30 
9.3 Statistical Analyses  ................................ ................................ ................................ .... 30 
9.3.1  General Considerations ................................ ................................ ...........................  30 
9.3.2  Primary Endpoint Analysis  ................................ ................................ .....................  30 
9.3.2.1  Definition of Endpoint(s) . ................................ ................................ ...................  30 
9.3.2.2  Main Analytical Approach  ................................ ................................ ..................  30 
9.3.2.3  Sensitivity Analyses  ................................ ................................ ............................  30 
9.3.2.4  Supplementary Analyses  ................................ ................................ .....................  30 
9.3.3  Secondary Endpoints Analysis  ................................ ................................ ...............  30 
9.4 Interim Analysis  ................................ ................................ ................................ .........  31 
9.5 Sample Size Determination  ................................ ................................ .......................  31 
10. Supporting Documentation and Operational Considerations  ................................  31 
10.1  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  ....................  31 
10.1.1  Regulatory and Ethical Considerations  ................................ ................................ .. 31 
10.1.2  Financial Disclosure  ................................ ................................ ...............................  32 
10.1.3  Informed Consent Process  ................................ ................................ ......................  32 
10.1.4  Recruitment Strategy  ................................ ................................ ..............................  32 
10.1.5  Data Protection  ................................ ................................ ................................ ....... 32 
10.1.6  Committees Structure  ................................ ................................ .............................  33 
CONFIDENTIAL  Clinical Study Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:  4 of 44 
 
10.1.7  Dissemination of Clinical Study Data  ................................ ................................ .... 33 
10.1.8  Data Quality Assurance  ................................ ................................ ..........................  34 
10.1.9  Source Documents  ................................ ................................ ................................ .. 34 
10.1.10  Study and Site Start and Closure  ................................ ................................ ............  35 
10.1.11  Publication Policy  ................................ ................................ ................................ ... 35 
10.2  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ...... 36 
10.3  Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting  ................................ ................................ ..........................  36 
10.3.1 Definition of AE  ................................ ................................ ................................ ..... 36 
10.3.2  Definition of SAE  ................................ ................................ ................................ ... 37 
10.3.3 Recording and Follow -Up of AE and/or SAE  ................................ ........................  38 
10.3.4  Reporting of SAEs  ................................ ................................ ................................ .. 40 
10.4  Appendix 4: Contraceptive and Barrier Guidance  ................................ .....................  40 
10.4.1  Definitions  ................................ ................................ ................................ ..............  40 
10.4.2  Contraception Guidance  ................................ ................................ .........................  42 
11. References  ................................ ................................ ................................ ....................  43 
 
Table of Tables  
Table 6 -1: Study Intervention Administered  ................................ ................................ ............  20 
Table 10 -1: Protocol -required Safety Laboratory Tests  ................................ ...........................  36 
 
Table of Figures  
Figure 1 -1: Schema  ................................ ................................ ................................ ....................  8 
 
  
CONFIDENTIAL  Clinical Study Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:  5 of 44 
 
List of Abbreviations  
ACCF  American College of Cardiology Foundation  
ACEI  angiotensin -converting enzyme inhibitor  
AE adverse event  
AESI  adverse event of special interest  
AHA  American Heart Association  
ALBI  albumin to bilirubin ratio  
ALT  alanine aminotransferase  
APaT  All-Participants -as-Treated  
ARB  angiotensin II receptor blocker  
ARNI  angiotensin receptor -neprilysin inhibitor  
AST  aspartate aminotransferase  
BP blood pressure  
CABG  coronary artery bypass grafting  
cGMP  cyclic guanosine monophosphate  
CIOMS  Council for International Organizations of Medical Sciences  
CKD -EPI Chronic Kidney Disease Epidemiology Collaboration  
CONSORT  Consolidated  Standards of Reporting Trials  
CRF  Case Report Form  
CRT  Cardiac resynchronization therapy  
CSR  Clinical Study Report  
CTFG  Clinical Trial Facilitation Group  
CTIS  Clinical Trials Information System  
CV cardiovascular  
ECG  electrocardiogram  
ECI event of clinical interest  
eCRF  electronic Case Report Form  
EF ejection fraction  
eGFR  estimated glomerular filtratio n rate  
EoS end of study  
ESC European Society of Cardiology  
EU European Union  
FDA  Food and Drug Administration  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
GDMT  guideline -directed medical therapy for heart failure  
hCG  human chorionic gonadotropin  
HF heart failure  
HFH  heart failure hospitalization  
HFrEF  heart failure with reduced ejection fraction  
HRT  hormone replacement therapy  
ICD implantable cardioverter -defibrillator  
ICF Informed Consent Form  
ICH International C ouncil  for Harmoni sation  of Technical Requirements for 
Pharmaceuticals for Human Use  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
IRT interactive response technology  
IUD intrauterine device  
IUS intrauterine hormone -releasing system  
IV intravenous  
LAM  lactational amenorrhea method  
LPLV  last patient last visit  
LVEF  Left ventricle ejection fraction  
MRA  mineralocorticoid receptor antagonist  
NO nitric oxide  
CONFIDENTIAL  Clinical Study Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:  6 of 44 
 
NSTEMI  non-ST elevation myocardial infarction  
NT-proBNP  N-terminal pro-brain natriuretic  peptide  
NYHA  New York Heart Association  
PCI percutaneous coronary intervention  
PDE5  phosphodiesterase type 5  
PD pharmacodynamic  
PID participant identification number  
PK pharmacokinetic  
QD once daily  
QTL  quality tolerance limit  
RAS  Renin -angiotensin -system  
SAE  serious adverse event  
SAF safety analysis set  
SBP systolic blood pressure  
SC subcutaneous  
sGC soluble guanylate cyclase  
SGLT2i  sodium -glucose cotransporter 2 inhibitor  
SmPC  summary of product characteristics  
SoA schedule of activities  
SOC  System Organ Class  
STEMI  ST elevation myocardial infarction  
SUSAR  suspected unexpected serious adverse reaction  
TIA transient ischemic attack  
UHF  urgent heart failure  
ULN  upper limit of normal  
UNS  unscheduled  
VICTOR  VerICiguaT GlObal Study in Participants With Chronic Heart Failure With Reduced 
Ejection Fraction  
VICTORIA  VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced Eject Ion 
FrAction  
WOCBP  woman/women of childbearing potential  
WONCBP  woman/women of nonchildbearing potential  
CONFIDENTIAL  Clinical Study Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:  7 of 44 
 
1. Protocol Summary  
1.1 Synopsis  
Protocol Title:  A Phase 2b open-label clinical study to evaluate the tolerability and 
safety of a starting dose of 5 mg of Vericiguat in participants with chronic heart failure with 
reduced ejection fraction  
Short  Title:  Vericiguat 5 mg initiation  study  
Regulatory Agency Identifier Number(s):  
Registry  ID 
EU CT:  2023 -507682 -25-00 
IND:   116, 743 
Envisaged indication:   
Chronic h eart failure with reduced ejection fraction  
Rationale:    
The objective of this study is to evaluate the tolerability of a 5 mg starting dose of vericiguat. 
The aim of this study is to generate evidence to support streamlining the titration regimen  
steps from 2 to 1 and enable HFrEF patients to achieve the target dose of 10 mg vericiguat 
daily within 1 titration step.  
Objectives , Endpoints:  
Objectives  Endpoints   
Primary   
• To evaluate the tolerability of 5 mg as a 
starting dose of vericiguat  • Treatment tolerability, defined as the 
complet ion of the two -week 5 mg dose 
without discontinuation of study intervention  
and without moderate to severe 
symptomatic hypotension between Visit 1 
and Visit 2.  
Secondary   
• To describe safety events of initiat ion of 
5 mg dose  
• To further evaluate the tolerability of 5 mg 
as a starting dose of vericiguat  • Any AE reported between Visit 1 and Visit 
2. 
• Absence of AE related to study intervention  
between Visit 1 and Visit 2 . 
• Continuous intake of study intervention  
between Visit 1 and Visit 2 or restart of 
study intervention after any temporary 
interruption.  
Overall Des ign Synopsis : 
This is multi -center, a single arm, open label study of vericiguat initiation at 5 mg in HFrEF 
patients with EF <45%. Participants wil l undergo a screening visit to assess eligibility. 
Eligible participants must wait a mandatory 2 weeks before returning for Visit 1  in order to be 
clinically and hemodynamically stable .  
At Visit 1,  participants will receive vericiguat with directions to t ake a 5 mg  tablet  once daily 
for 2 weeks . Participants will return for Visit 2  after 2 weeks of treatment.  
Unscheduled visits may be utilized  between Visits 1 and 2  at the discretion of the  investigator.  
CONFIDENTIAL  Clinical Study Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:  8 of 44 
 
Number of Participants:  
Approximately 120 participants will be screened to achieve at least 100 participants who are 
assigned  to study  intervention  and complete the treatment period of up to 2 weeks . 
Study Arms and Duration : 
This is a single arm, open label study. The total study duration is approximately 4 weeks , 
including a 2 -week screening period  and a  2-week treatment period . 
Data Monitoring /Other  Committee:  Yes 
 
1.2 Schema  
Figure 1-1: Schema  
 
A = assignment to study intervention , D = day, EoS = end of study, S= screening, V = visit  

CONFIDENTIAL  Clinical Study Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   9 of 44 
 
1.3 Schedule of Activities (SoA)  
Visit Number  Screening  V1 V2b UNS c Notes  
Study  Day, Window  D -14 D1 D14   
Window (Days)  -4 a  +4   
Informed consent  X     
Inclusion and exclusion criteria  X X   Recheck clinical status before assignment and/or 1st dose of study intervention . 
Demography  X     
Full physical examination 
including height and weight  X     
Optional: local lab - clinical 
chemistry , hematology  X    eGFR, albumin, hemoglobin, total bilirubin, ALT and AST values must be available at 
screening. Values obtained as part of routine management should be used if measured within 
30 days prior to Visit 1 . If data is unavailable, values should be determined using a local lab.  
Serum OR urine pregnancy test 
(WOCBP only)   X   If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy 
test is required.  
Medical history  X    Includes  substance usage and family history of premature CV disease  
Current status of heart failure 
medical conditions   X X  Collect any changes to heart failure medical condition (hospitalization, worsening of condition).  
Prior and current medications  X X X X Assess at any visit including daily dose, time of intake and dosing regimen  
Local 12 -lead ECG  X     
Vital signs  X X X X Vital signs should be  measured before study intervention intake . See Section 8.3.2 . 
Study Intervention Assignment   X    
Intake of Study Intervention   X   Study intervention should be taken orally with food at the same time each day, preferably in the 
morning.  Date and time of study intervention intake will be recorded at Visit 1. Participants 
must remain at the site for 2 h after intake of first dose of study intervention. Study intervention 
is self -administered between Visit 1 and Visit 2. See Section  6 for additional details. .  
Study Intervention Accountability    X X  
AE review   X X X See Section 8.4.Includes AESI. At Visit 1, the AE review should be conducted before and 2h 
after dosing. If AE review is suggestive of symptomatic hypotension, date, time, and severity  
will be recorded and vital signs should be re-assessed  post dose .  
AE = adverse event, AESI = adverse event of special interest, ALT = alanine transaminase, AST = aspartate aminotransferase, CV = cardiovascular, D = day, 
ECG = electrocardiogram, UNS = unscheduled, V = visit, WOCBP = women of child -bearing potential  
a Screening must be completed 14 -18 days before Visit 1.  
b Visit 2 is the end of intervention visit.  
c For Unscheduled Visits  for AE review and reporting , assessments indicated in the SoA are mandatory. All other pr ocedures selected and performed at 
unscheduled visits are at the discretion of the investigator and as clinically indicated.  
 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   10 of 44 
 
2. Introduction  
Chronic HFrEF is a major source of morbidity and mortality. Clinical outcomes for patients 
with chronic HFrEF remain poor, despite contemporary evidence -based therapies. Therefore, 
drugs are needed that effectively target disease mechanisms not addressed b y current standard 
therapy.  
Vericiguat, a novel soluble sGC stimulator, is approved for the treatment of HFrEF. 
Decreased NO availability, sGC desensitization to NO, sGC deficiency, and cGMP signaling 
are potential contributing factors for HF disease prog ression. Vericiguat works via stimulation 
of sGC in the critical NO -sGC-cGMP pathway. Vericiguat has a novel mode of action that 
targets endothelial dysfunction to improve regulation of vascular tone and myocardial 
function . Pharmacokinetic, pharmacodynami c, safety and efficacy profiles of vericiguat have 
been well characterized in a series of Phase 1 (29 studies), Phase 2 (3 studies) and Phase 3 (1 
study)  studies . In the global Phase 3 study , VICTORIA, treatment of 5050 patients with 
chronic HF with reduce d ejection fraction with vericiguat on top of the standard of care 
resulted in a 10% reduction in the primary outcome of a composite of death from 
cardiovascular causes or first hospitalization for HF after a median treatment period of 10.8 
months (Armstrong et al. 2020) .   
In VICTORIA, vericiguat was generally safe and well tolerated with low incidence of 
symptomatic hypotension and syncope, using  a titration regimen (a starting dose of 2.5 mg 
followed by a 2 -step up -titration to the target 10 mg dose) guided by symptoms and SBP to 
mitigate the risk of hypotension. Correlation between vericiguat plasma concentrations and 
hemodynamic parameters such  as heart rate and SBP has been observed following first dose 
administration but dissipated with repeated dosing . In addition, no meaningful exposure -
response relationship was observed for the incidence of symptomatic hypotension or syncope 
– after first d ose and further during the study. This led to the implementation of a symptom - 
and SBP -guided 2-step titration scheme for vericiguat posology. A detailed description of the 
chemistry, pharmacology, efficacy, and safety of vericiguat  is provided in the inve stigator’s 
brochure.  
2.1 Study Rationale  
The objective of this study is to evaluate the tolerability of a 5 mg starting dose of vericiguat 
in HFrEF patients; the aim of the study is to generate evidence to support streamlining the 
titration regimen from 2 step s to 1 step and enable HFrEF patients to achieve the target 
maintenance dose of 10 mg vericiguat daily.  
2.2 Background  
In clinical practice , titration of HF medications, including vericiguat, is often compromised by 
limited follow -up opportunities and complexi ty of care at each follow -up visit. This results in  
under treatment of HFrEF patients due to failure to achieve the maximum efficacious dose  for 
treatments with established benefit . Achieving the target dose of HF treatments in a safe and 
fast manner remai ns a large unmet medical need in HFrEF patients. Keeping drug 
initiation/titration regimens as simple and as safe as possible is critical to HFrEF patients in 
order to achiev e optimal doses of GD MT.  
Currently, i nitiation of vericiguat starts with 2.5  mg, increasing to 5  mg at 2 weeks, then 
10 mg at 4 weeks.  Removing the 2.5 mg step has the benefit of patients starting on a more 
efficacious dose and achieving maximal (target) dose with a single titration. In VICTORIA,  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   11 of 44 
 
>80% of HFrEF participants were succes sfully titrated to the 10 mg dose ,  with minimal 
decrease in blood pressure after placebo adjustment, such that only 10% of patients remained 
on the starting dose of 2.5 mg of vericiguat, similar to 9% remaining on “2.5 mg” after sham 
titration in the plac ebo arm. Indeed, in VICTORIA, f ollowing initiation of the 2.5 mg starting 
dose, 96.1% of participants on vericiguat and 96.4% of those on placebo remained on 
treatment through the day 14 visit without interruption . 
During the first 14 days of treatment wit h vericiguat, adverse event s of clinical interest  of 
symptomatic hypotension or syncope occurred in 2.0% of those on vericiguat and 1.2% of 
those on placebo. It was also observed that a slightly higher incidence of hypotensive events 
was seen in vericiguat  arm during first 1 -2 weeks since initiation but not later in titration.  
Another large clinical trial, VICTOR, currently underway is assessing the efficacy and 
tolerability of vericiguat compared with placebo in stable HFrEF patients treated with current 
GDMT  (Heidenreich et al. 2022, McDonagh et al. 2021) .  Overall , there  is a pertinent need to 
investigate the effects of vericiguat in optimally treated, low er-risk HFrEF patients (i.e. those 
without recently worsening heart failure).  
In a real -world setting, t wo sets of data on the use of vericiguat are available : one in th e US 
and one in German y.  
In the U nited States (Victores et al. 2023) , among 3 ,578 patients treated with vericiguat (mean 
age 67.4 years, 68.1%  male) , only 34% reaching the target dos e of 10 mg. This was more 
likely to occur in patients treated by SGLT2i or on both ARNi and SGLT2i.  
In Germany  (Kerwagen et al. 2023) , during the 16 -month study period since the launch of 
vericiguat in September 2021, initiation of vericiguat was observed in n=2,916 (median age 
75 years, 72% male)  patients . During a medi an follow -up of 150 days, 33% of the patients 
reached the 5 mg, and 36%  reached  the 10 mg dose.  
This real -world data provides background to explore initiating treatment at dose 5 mg to 
achieve the 10 mg target dose of vericiguat in a safe and faster manner . 
2.3 Benefit/Risk Assessment  
The results of the VICTORIA study showed a favorable benefit -risk profile for the use of 
vericiguat in patients with chronic HFrEF following a recent worsening event .  In 
VICTORIA ,  patients were allowed to titrate to the target dose of 10 mg . Vericiguat has a 
clinically meaningful benefit on the endpoints of HF  hospitalizations  and CV  death. The AE 
profile in VICTORIA was predominantly associated with vericiguat’s mechanism of action  as 
a sGC stimulator (i.e., relaxati on of smooth muscle leading to vasodilation, hemodynamic 
changes and gastrointestinal side effects) .  
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of vericiguat  may be found in the VERQUVO  Investigator’s 
Brochure  and approved labeling . 
2.3.1 Risk Assessment  
The general risks of vericiguat are known . During the VICTORIA study, AEs more frequently 
reported in the vericiguat group compared to placebo included hypotension, dyspepsia, 
nausea, dizzines s, and headache . Anemia was also more frequently reported in the vericiguat 
group compared to placebo . Similar results were reported with riociguat, another sGC 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   12 of 44 
 
stimulator . Overall, these events are generally non serious  and manageable  (Ghofrani et al. 
2013a, Ghofrani et al. 2013b) . 
Pharmacokinetic -pharmacodynamic (PK -PD) analysis of SOCRATES -REDUCED and 
VICTORIA revealed  a small but statistically significant linear relationship between the 
change in SBP from baseline to 2 hours post dose and the measured vericiguat C max (PH-
38550 2020, R -13340 2020)  following initiation of vericiguat treatment . However, no 
statistically significant relationship was observed between C max and changes in SBP from 
baseline at later visits , suggesting that subsequent titrations to higher doses had minimal 
hemo dynamic effects . 
Based on PK-PD modeling of data from  SOCRATES -REDUCED, the mean SBP is predicted 
to decrease from baseline by an additional  2.0 to  2.5 mmHg  (i.e., a 4.0 -5.0 mmHg total 
decrease) when the starting dose is increased from 2.5 mg to 5 mg  (i.e. when exposure is 
doubled ) (PH-38545 2015, PH -38550 2020) .  
The pharmacod ynamic effects of vericiguat were evaluated after single and multiple -dose 
administrations in healthy participants. All tested doses (up to 15  mg) were administered  with 
ad-hoc dosing (without titration) . In a pooled analyses across Phase 1 healthy partici pant 
studies, the most frequent AEs were  headache, dyspepsia and dizziness , consistent with the 
predicted effects of an sGC stimulator on smooth muscle relaxation and vasodilation  (PH-
40726 2020) . Generally, the incidence of AEs decreased  after multiple dosing and when taken  
with food as directed  (for details, see Section 4.3).  
Overall, the anticipated risks associated with a starting dose of 5 mg of vericiguat are deemed 
in line with the  established  safety profile of the product . 
In addition, the risk assessment  will involve addressing risks related to the use of SGLT2i and 
ARNI in the study population as we foresee an adoption of these classes larger than in 
VICTORIA based on current GDMT . Both VICTORIA and VICTOR included 
recommendations  to treat participants  to GDMT; however, given the time lapse between the 
two studies, the recommendations were to different standards. VICTORIA included 
approximately 15% of patients on ARNI  at randomization  and only 3% of patients on SGLT2i  
after randomization , while VICTOR pro tocol encourages use of ARNI and SGLT2i at 
baseline with goals of at least 30% and 15% , respectively . 
2.3.2 Benefit Assessment  
The results from the Phase 3 VICTORIA study provide evidence of an important clinical 
benefit of vericiguat in adult patients with symptomatic chronic HF and ejection fraction less 
than 45% following a worsening HF event. Although participants of the  present  study are 
unlikely to benefit from the st udy intervention directly due to the short duration of treatment 
with vericiguat not achieving the target dose,  reducing the current titration regimen from 2 
steps to 1 step will  enable HFrEF patients to achieve the target dose of 10 mg vericiguat daily 
in a shorter period of time while starting on a dose with higher pharmacological activity.  
2.3.3 Overall Benefit: Risk Conclusion  
Vericiguat is a new therapeutic option to fulfill the unmet medical need in patients with 
chronic HFrEF. Based on current clinical evi dence, vericiguat provides an important clinical 
benefit to adult patients with symptomatic chronic HFrEF, and is well tolerated at doses up to 
10 mg daily. T he currently known risks  associated with the mechanism of action  are deemed 
well characterized . With the higher starting dose of 5 mg only a small decrease in blood 
pressure of about 4.0-5.0 mmHg is expected after administration of the first dose.  In order t o 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   13 of 44 
 
manage potential side effects, pa rticipants  will be asked to stay at the site for 2 hours afte r the 
first dos e. 
Considering  the measures taken to minimize risks to participants in this study  and the 
expected clinical benefit in patients with worsening HF, the benefit/risk assessment is 
considered positive and the conduct of the planned study in heart failure patients who will not 
directly benefit from the study  intervention is justified . 
3. Objectives , Endpoints  
Objectives  Endpoints  
Primary   
• To evaluate the tolerability of 5 mg as a 
starting dose of vericiguat  • Treatment tolerability, defined as the 
completion of  the two -week 5 mg dose 
without discontinuation of study intervention 
and without moderate to severe symptomatic 
hypotension between Visit 1 and Visit 2.  
Secondary   
• To describe safety events of initiati on of 
5 mg dose  
• To further evaluate the tolerability of 5 mg 
as a starting dose of vericiguat  • Any AE reported between Visit 1 and Visit 2.  
• Absence  of AE related to study intervention 
between Visit 1 and Visit 2.  
• Continuous intake of  study intervention 
between Visit 1 and Visit 2 or restart of study 
intervention after any temporary interruption.  
4. Study Design  
4.1 Overall Design  
This is a single arm, open label study of vericiguat initiation at 5 mg in HFrEF patients with 
EF <45%. The total study duration is approximately 4 weeks, including a 2 -week screening 
period  and a 2-week treatment period . 
Screening : Approximately 120 participants will be screened to achieve at least 100 
participants who are assigned to study  intervention  and complete the treatment period of up to 
2 weeks . Participants will undergo a screening visit to assess eligibility. Eligible participants 
must wait a mandatory 2 weeks before  returning for Visit 1  in order to be clinically and 
hemodynamically stable .  
Trea tment : At Visit 1, participants will receive vericiguat 5 mg (on top of standard of care)  
with directions to take once daily for 2 weeks.  Participants will return for Visit 2 after 2 
weeks of treatment.  
Unscheduled visits may be utilized  between Visits 1 and 2  at the discretion of the  investigator  
for AE review and reporting .  
4.2 Scientific Rationale for Study Design  
The objective of this study is to evaluate the tolerability of a 5 mg starting dose of vericiguat. 
The current dosing regimen for vericiguat requires a 2 -step titration to the target dose of 
10 mg; the initial dose of the 2 -step titration is 2.5 mg. The aim of this  study is to generate  
evidence to  support streamlining the titration steps from 2 to 1 and ease reaching the target 
dose of 10 mg vericiguat daily.   
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   14 of 44 
 
The proposed study aims at providing evidence of tolerability of initiating treatment with a 
starting dose of 5 mg vericiguat. Tolerability of the subsequent up -titration step from 5 mg to 
10 mg has been extensively investig ated in VICTORIA and is currently being investigated in 
VICTOR. Thus, in this respect, a 2 -week study is considered to provide the additional 
evidence for the evaluation of 5 mg as a starting dose with the aim to support a 1 -step titration 
regimen.  
The target population for this study is adults with chronic HFrEF with EF < 45% with and 
without a recent (<6 months) worsening HF event. This study population therefore is 
representative of  the patient populations of both VICTORIA and VICTOR.  Vericiguat w as 
shown to improve outcomes in patients with HFrEF in the VICTORIA trial , which  included 
patients with recent  worsening HF. VICTOR is  evaluating the efficacy and safety of 
vericiguat  in lower -risk HFrEF patients. Indeed , all key HFrEF medications have bee n 
evaluated in both higher - and lower -risk populations, and the treatment effect was not always 
consistent across the risk spectrum. Furthermore , post -hoc analyses of the VICTORIA trial 
have suggested that sGC stimulators may have cardioprotective effects that may be more 
apparent when the medication is initiated earlier in the disease process. Finally , the effect of 
vericiguat on cardiovascular mortality was uncertain in VICTORIA and a trial of vericiguat 
with a longer follow -up in a lower -risk HFrEF population such as VICTOR may shed light  on 
its effect on cardiovascular mortality.   
The present study will support initiation of vericiguat at 5 mg dose, streamlining the titration 
regimen from 2  steps  to 1 step and enabl ing all HFrEF patients to achieve the target dose of 
10 mg vericiguat daily within 1 titration step . In order to support the posology section change  
in the current (worsening HF) and the expanded (stable HFrEF) label , conditional to a 
positive outcome of VICTOR , there is a pertinent need to investigate the effects of vericiguat 
in both optimally treated, high-risk (with a recent worsening heart failure event ) and low-risk 
(without a recent worsening heart failure event) HFrEF patients.  These two subpopulations  in 
this study  are intended to be comparable to those addressed in VICTORIA and VICTOR, in 
terms of demographics, severity of disease and comorbidities, with the potential difference 
stemming from  a better background treatment  compared with VICTORIA,  based on  the latest 
standards of GDMT.   
Vericiguat’s mechanism of action results in increased intracellular cGMP levels in cardiac 
myocytes and smooth muscle cells. These changes are associated with smooth muscle 
relaxation and a reduction in vascular tone. Throug hout the clinical development of 
vericiguat, dose up -titration was dependent upon maintaining adequate SBP and the presence 
or absence of hypotensive symptoms. Tolerability  and safety monitoring during this study 
will focus on continuation of study interve ntion and absence of symptomatic hypotension  of 
moderate to severe intensity . 
4.3 Justification for Dose  
The study will assess the tolerabilit y of a starting dose of 5 mg vericiguat, once daily.   
In the initial clinical pharmacology studies in healthy volunteers, 5 mg (and 10 mg ) of 
vericiguat were administered as an initial dose and were well tolerated  (Boettcher et al. 2021) . 
The approved target dose and titration regimen for vericiguat  are based on data from the 
Phase  1 program in healthy volunteers, the Phase  2b study SOCRATES -REDUCED in 
HFrEF, and the Phase  3 VICTORIA  study in HFrEF . The goa l of the present study is to 
provide tolerability and safety  evidence to enable starting treatment on dose 5 mg.  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   15 of 44 
 
Several stepwise titration schemes were assessed in the Phase 2 SOCRATES -REDUCED 
trial, with titration guided by clinic -based BP measurements i n each scheme. Comparison of 
NT-proBNP reduction from baseline at 12 weeks across titration schemes demonstrated a 
clear trend of larger reductions in NT -proBNP in those titrated to higher target vericiguat 
doses. The greatest reduction occurred in those t itrated to a target dose of 10 mg with this 
target also having an acceptable safety profile. This led to the 2.5 mg to 5.0 mg to 10 mg 
titration scheme being adopted for the VICTORIA trial. In VICTORIA, up - and down -
titration  at the study visits  was guided by SBP and the presence or absence of symptomatic 
hypotension. Overall, this titration regimen was well tolerated and a total of 74% of 
participant s reached the 10 mg target by the end of the titration period ( 73% of those 
randomized to vericig uat; 75% of those randomized to placebo;); for participants followed for 
up to one year, 90% reached 10 mg ( 89% of those randomized  to vericiguat ; 91% of those 
randomized to placebo).  
Over the course of VICTORIA, the effect of vericiguat on BP was small, with mean SBP 
generally <  2 mmHg lower in those treated with vericiguat compared to placebo. The main 
blood pressure effect was observed early after the first 2.5 mg dose of vericiguat (SBP 
reduction of about 3 mmHg) in participants who received vericiguat  compared with placebo. 
This small vericiguat -induced decrease in BP did not translate into a  meaningful exposure -
response relationship for the incidence of symptomatic hypotension or syncope – after first 
dose and during the further study.  
PK-PD analysis  of SOCRATES -REDUCED and VICTORIA revealed  a small hemodynamic 
effect (2.0-2.5 mmHg SBP reduction) following initiation of vericiguat treatment , but 
subsequent titrations to higher doses had minimal hemodynamic effects . Based on PK/PD 
modeling of data from  SOCRATES -REDUCED , an additional 2.0-2.5 mmHg (i.e., 4.0-
5.0 mmHg total) decrease in SBP is predicted when the starting dose is increased from 2.5 mg 
to 5 mg. 
Finally, symptomatic hypotension and syncope events were collected as events of clinical 
interest  in VICTORIA. Randomization to vericiguat resulted in a 1.8 percentage point 
increase of reported events of clinical interest  of symptomatic hypotension or syncope 
compared to placebo  over the duration  of the study . These ECIs were more frequent during 
the earlier phases of the titration, though no clustering of symptomatic hypotension events 
was observed following the very first dose, or immediately following each titration step . 
4.4 End-of-Study Definition  
The end of the study and primary completion date are  defined as the date of the last visit of 
the last participant in the study globally.  
A participant is considered to have completed the study if he/she has completed  Visit 2  (end 
of intervention visit) .  
5. Study Population  
The study will enroll participants with chronic heart failure with ejection fraction <45%, with 
and without recent  worsening HF. Enrollment  caps will be applied to ensure enrollment of the 
desired proportion of participants with (group 1) and without  (group 2)  recent HF event  
(approximately 50% in each group).  These two groups will also  reflect contemporary 
standards of care in HF, with a goal of  enrolling at least 30% of participants receiving an 
ARNI and 30%  a SGLT2 inhibitor.  The desired proportion of participants on GDMT may  be 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   16 of 44 
 
achieved by capping the number of participants not on ARNI or SGLT2i therapy . These 
enrollment caps  will be managed  in the IRT.  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known 
as protocol waivers or exempt ions, is not permitted.  
5.1 Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant s (male and female)  must be ≥18 years of age at the time of signing the  
informed consent.  
Type of P articipant and Disease Characteristics  
2. Has an LVEF of <45% assessed within 12 months before Visit 1  by local any 
imaging method , and no subsequent LVEF measurement  > 45% . The most recent 
measurement must be used to determine eligibility.  
NOTE: Participants who have undergone a coronary revascularization (PCI or 
CABG), valve repair/replacement, or implantation of CRT device or any 
other surgical, device, or pharmacological intervention ( i.e., initiation of a 
GDMT) that might improve LVEF, must ha ve a measurement of LVEF 
<45% at least 3 months after the intervention to be eligible . 
3. SBP ≥ 100 mmHg  at screening  and Visit  1 (pre-treatment ). 
4. No changes in GDMT  dosing  (including beta  blockers, ACEI/ARBs, ARNI, MRAs, 
hydralazine -nitrate combinations, SGL T2 inhibitor s, ivabradine , or oral diuretics )  
• Within 4 weeks of screening for participants with out a HF event ≤6 months 
prior to  screening  
• within 2 weeks of screening for participants with a HF event ≤6 months prior 
to screening  
• planned during study participation  
5. No expected medical procedures to occur  2 weeks  before screening or during  study 
participation .  
6. Participants with ( group 1)  OR without (group 2) recent worsening HF  event   
Group 1:  History of chronic HF (NYHA class II symptomatic -IV) on GDMT with 
recent HF event within 6 months of screening  or outpatient IV / SC diuretic use 
within 3  months before screening . 
 
OR 
 
Group 2: History of chronic HF (NYHA class II symptomatic -IV) on GDMT 
without recent HF event  within 6 months of screening  or outpatient IV / SC 
diuretic use within 3  months before screening . 
Sex and Contraceptive/Barrier Requirements  
7. Male or female  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   17 of 44 
 
Contraceptive use by men and women  should be consistent with local regulations regarding 
the methods of contraception for those participating in clinical studies.  
Male participants:  No measures.  
Female participants :  
• A female participant is eligible to participate if she is not pregnant or  breastfeeding, 
and one of the following conditions applies:  
• Is a woman of nonchildbearing potential (WONCBP) as defined in Section 
10.4. 
OR 
• Is a WOCBP and using a contraceptive method that is highly effective 
(with a failure rate of < 1% per year), with low user dependency, as 
described in Section 10.4 during the study intervention period and for at 
least 1 month  after the last dose of study intervention. The investigator 
should evaluate the potential for contraceptive method failure (e.g., 
noncompliance, recently initiated) in relationship to the first  dose of study 
intervention.  
• A WOCBP must have a negative  highly sensitive pregnancy test (urine or serum as 
required by local regulations) within  24h before the first dose of study intervention, 
see Section  8.3.5 .  
• If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a 
serum pregnancy test is required. In such cases, the participant must be 
excluded from participation if the serum pregnancy result is positive.  
• Additional requirements for preg nancy testing during and after study intervention are 
located in Section  8.3.5 . 
• The investigator is responsible for review of medical history, menstrual history, and  
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.  
Informed Consent  
8. Capable of giving signed informed consent as described in Section 10.1.3  which 
includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol.  
5.2 Exclusion Criteria  
Participants are excluded from the study i f any of the following criteria apply:  
Cardiac conditions  
1. History of symptomatic hypotension  4 weeks before screening . 
2. Primary valvular heart disease requiring surg ical procedure  or intervention or has 
undergone a valvular  surgical procedure  or interventio n within 3  months before 
Visit 1 . 
3. Hypertrophic cardiomyopathy . 
4. Acute myocarditis  or Takotsubo cardiomyopathy . 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   18 of 44 
 
5. Awaiting heart transplantation (United Network for Organ Sharing Class 1A /1B 
or equivalent)  or has or anticipates receiving an implanted ventricular assist 
device, or has received a heart transplant.  
6. Tachycardia -induced cardiomyopathy and/or uncontrolled tachyarrhythmia.  
7. Acute coronary syndrome (unstable angina, NSTEMI, or STEMI), undergone 
CABG or PCI within 3  months before Visit 1 , or ind ication for coronary 
revascularization at the time of treatment assignment . 
8. Symptomatic  carotid stenosis, TIA, or stroke within 3  months  before Visit 1 . 
9. History of repaired or unrepaired simple congenital heart disease ( e.g., atrial or 
ventricular septal d efects, or patent ductus arteriosus) with ongoing 
hemodynamically significant residual lesions, or any history of complex 
congenital heart disease ( e.g. tetralogy of Fallot, transposition of the great arteries, 
single ventricle disease) regardless of repai r status.  
10. Active endocarditis or constrictive pericarditis.  
11. Hemodynamic instability or hypovolemia  within 4 weeks of screening  and during 
the screening period .  
Medical Conditions  
12. Currently hospitalized . 
13. eGFR based on the CKD -EPI Creatinine Equation  of <15 mL/min/1.73  m2 within 
30 days before Visit 1  or on  chronic dialysis.  For participants with multiple eGFR  
results during screening, the most recent value will be used to determine 
eligibility.  
14. Severe hepatic insufficiency defined as ALBI Grade 3 or hepatic  encephalopathy, 
or has hepatic laboratory abnormalities (ALT or AST ≥3  × ULN or total bilirubin 
≥2 × ULN).  Exceptions for Gilbert’s syndrome will be considered.  Albumin , 
ALT, AST,  and total bilirubin results within 30  days before Visit 1  may be used 
for assessment of laboratory abnormalities or the calculation of the ALBI score . 
For participants with multiple albumin and/or total bilirubin results during 
screening, the most recent value for each test will be used to calculate ALBI 
score.   
15. Malignancy or ot her noncardiac condition limiting life expectancy to <3  years.  
16. Requires continuous home oxygen for severe pulmonary disease.  
17. Interstitial lung disease.  
18. Known allergy or hypersensitivity  to vericiguat, any of its constituents,  or any 
other sGC stimulator.  
19. Amyloidosis or sarcoidosis . 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   19 of 44 
 
Prior/Concomitant Therapy  
20. Concurrent or anticipated concomitant use of PDE5 inhibitors such as vardenafil, 
tadalafil, and sildenafil during the study.  
21. Concurrent use of an sGC stimulator such as riociguat or vericiguat.   
22. Prior ( within  2 weeks prior to screening) or anticipated concomitant 
administration of IV / SC diuretics or inotrope s.  
Prior/Concurrent Clinical Study Experience  
23. Participated in another interventional clinical study or has been treated with 
another investigation al product ≤30  days before Visit 1  or plans to participate in 
any other study or study intervention during this study.  
Other Exclusion Criteria  
24. Recent  history (within the last year) of drug or alcohol abuse or dependence . 
25. Is pregnant or breastfeeding or pl ans to become pregnant or to breastfeed during 
the study.  
26. Medical  disorder, condition, or history thereof that in the opinion of the 
investigator would impair the participant’s ability to participate in or complete the 
study.  
27. Is or has an immediate family member (e.g., spouse, parent/legal guardian, 
sibling, or child) who is investigational site or Sponsor staff directly involved with 
this study.  
5.3 Lifestyle Considerations  
No restrictions required.  
5.4 Screen Failures  
A screen failure occurs when  a participant who has consented  to participate in the clinical 
study but is not subsequently assigned to study intervention  (vericiguat) . A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure 
participants to meet the C ONSORT publishing requirements and to respond to queries from 
regulatory authorities. Minimal information includes demography, screen failure details, last 
visit date and SAE . 
Individuals who do not meet the criteria for participation in this study (screen  failure) may be 
rescreened  once . The following conditions are pre -requisites of re -screening:  
• A minimum of 1 month between the initial Screening visit and re -screening.  
• Before re -screening, new documented informed consent must be obtained .  
• Allocation of  a new participant identification number . 
• All screening assessments for the study must be repeate d. 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   20 of 44 
 
5.5 Criteria for Temporarily Delaying  Study Intervention  
Not applicable.  
6. Study Intervention  and Concomitant Therapy  
Study interventions are all pre -specified, investigational and non -investigational medicinal 
products, medical devices and other interventions (e.g., surgical and behavioral) intended to 
be administered to the study participants during the study conduct.  
Refer to the approved labeling  / most recent  investigator’s brochure  for vericiguat for more 
details regarding study intervention  properties and formulation.  
6.1 Study Intervention Administered  
Study intervention should be taken orally with food at the same time each day , preferably in 
the morning.  If a dose is missed, it should be taken as soon as the participant remembers on 
the same day of the missed dose. But there should be consistency with respect to dosing 
intervals (the recommendation is to have at least a 20 -hour interval between doses).  
Partic ipants should not take 2 doses of study intervention on the same day.  The investigator 
should be informed if the dose of Vericiguat taken has exceeded the scheduled dose.  
 
Table 6-1: Study Intervention Adminis tered  
Intervention Label  Vericiguat  
Intervention Name  Vericiguat  
Intervention Description  Tablet 5 mg/day  
Type  Small molecule d rug 
Dose Formulation  Tablet  
Unit Dose Strength(s)  5 mg  
Dosage Level(s)  1 x 5  mg d aily for 14 (+4) days  
Route of Administration  Oral 
Use Experimental  
Sourcing  Vericiguat will be provided centrally by the Sponsor.  
Packaging and Labeling  Vericiguat tablets are available in high density 
polyethylene  (HDPE)  bottles with a white child 
resistant closure and induction seal. The packaging 
configuration is 18 tablets Vericiguat 5  mg per bottle. 
The bottles  will be labelled  as required per country 
requirement . 
Current/ Former Name(s) or Alias(es)  VERQUVO ®, BAY 1021189  
 
6.2 Preparation , Handling , Storage , and Accountability  
1. Only participants enrolled  in the study may receive study intervention and only 
authorized site staff may supply , prepare  or administer study intervention .  
2. All study intervention must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   21 of 44 
 
3. The investigator is responsible for study inter vention accountability, reconciliation, 
and record maintenance ( i.e., receipt, reconciliation, and final disposition records).  
Study i ntervention  returns, reconciliation and destruction return  information will be 
captured in IRT.  
4. Further guidance and information for the final disposition of unused study 
interventions are provided in the site file .  
Handling/Storage/Accountability at the participant’s home  
Participants will follow the instructions provided by authorized site staff f or storage and 
administration of study intervention at home, as well as for return of unused study 
intervention to the site.  
6.3 Assig nment to Study Intervention  
Randomization is not applicable for the study. All participants will receive the same study 
interv ention.  
All participants will be centrally assigned to the study intervention using an IRT.  Enrollment 
caps defined in Section 5 will be managed by the IRT. Parti cipants   will be given a unique 
PID (9 digit number)  at the start of screening . The PID consists of a unique country number 
(digits 1 to 2),  unique center number (digits 3 to 5) and the participant number within the 
center (digits 6 to 9).  Participants who meet the entry criteria will be sequentially assigned to 
a treatment allocation number  (TNR ) in ascending order.  
6.4 Blinding  
Not applicable.  This is an open label study.  For details on ensuring data integrity, see Section 
9.4. 
6.5 Study Intervention Compliance  
A participant will receive exactly one bottle of vericiguat 5  mg tablets containing 18 tablets 
for any unforeseen events (e.g. loss or damage of single tablets or to allow for visit window).  
Compliance with study intervention  (vericiguat ) self-administered at home between Visit 1 
and Visit 2 , will be assessed at Visit 2 (Day 14) . Compliance will be assessed by counting 
returned tablets  during the s ite visit and documented in the source documents and relevant 
form .  
Deviation(s) from the prescribed dosage regimen should be recorded . Any discrepancies 
between actual and expected amount of returned study intervention must be discussed with 
the particip ant at the time of the visit, and any explanation must be documented in the source 
records. An adequate record of receipt, distribution, and return/destruction of all study 
intervention must be kept.  
A record of the quantity of vericiguat tablets  dispensed  to and administered by each 
participant must be maintained and reconciled with study intervention and compliance 
records. An adequate record of receipt, distribution, and return/destruction of all study 
intervention  must be captured on the dispensing log and/or in the IRT . Intervention start and 
stop dates, including dates for intervention delays will also be recorded  in the CRF/ eCRF .  
Participants will be instructed to take study intervention as scheduled, and to return all of the 
study intervention packaging including unused study intervention and empty packaging.  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   22 of 44 
 
Study intervention  tablets not returned will be considered to have been taken unless otherwise 
specified. At the end of the study, any remaining study intervention  will be collected and 
destroyed  as per local regulations . Any discrepancies between the returned and expected 
returned study intervention  should be explained.  
6.6 Dose Modification  
The intention of the protocol is to maintain participants  on the 5 mg dose of study intervention 
for the 2-week treatment period . Dose modifications are not planned within the scheme of this 
study.  See Section 7.1.1  for details on temporary  discontinuation  of study i ntervention . 
6.6.1 Retreatment Criteria  
All participants entered into the study will be treated from Day 1 to Day 14 inclusive.  See 
Section 7.1.2  for details on treatment resumption after temporary interruption of study 
intervention.  
6.7 Continued Access to Study Intervention after the End of the Study  
No continued access to the study inte rvention is planned following the end of the stud y. 
Participants may continue treatment on commercially available vericiguat at the discretion of 
their treating physician.  
6.8 Treatment of Overdose  
In this study, an overdose is any dose higher than 5  mg veric iguat QD.  
Limited data are available with regard to overdosage in patients treated with vericiguat. In the 
event of an overdose, hypotension may result. Symptomatic treatment should be provided. 
Vericiguat is unlikely to be removed by hemodialysis because of high protein binding.  
In the event of an overdose, the investigator should:  
• Evaluate the part icipant to determine, in consultation with the medical monitor, if 
possible , whether study intervention should be interrupted or whether  the dose should 
be redu ced. 
• Closely monitor the participant for any AE/SAE and laboratory abnormalities  
• Document the quantity of the excess dose as well as the duration of the overdose.  
Decisions regarding dose interruptions or modifications following a suspected overdose will 
be made by the investigator in consultation with the medical monitor  based on the clinical 
evaluation of the participant.  
 
6.9 Prior and Concomitant Therapy  
Any medication or vaccine (including over -the-counter or prescription medicines, recreational 
drugs, vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrollment or receives during the study must be recorded along with:  
• Reas on for use  
• Dates of administration including start and end dates  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   23 of 44 
 
• Dosage information including dose and frequency  
All participants should receive GDMT based on locally relevant guidelines such as ESC and 
ACC/AHA Guidelines for Management of Heart Failure ap plied individually to the discretion 
of the treating investigator and in line with individual tolerability, aiming at reflecting the 
current standard of care in the largest proportion of patients  (Heidenreich et al. 2022, 
McDonagh et al. 2021) . This includes medications such as beta  blockers, ACEIs, ARBs, 
ARNI, MRAs, hydra lazine -nitrate combinations, SGLT2  inhibitor s, ivabradine, and cardiac 
device therapies such as ICDs and biventricular pacemakers. At least 30% of participants 
receiving  an ARNI and 30%  a SGLT2i should be enrolled in the study in order for the study 
to meet contemporary GDMT standards . Dose changes in GDMT medications (RAS 
blockade, Beta -blocker, MRA, or SGLT2i) or oral diuretics should be discouraged, except 
when mandated by known side -effects for individual drug classes (e.g., hyperkalemia for 
MRA or a ngioedema for ACE -inhibitors / ARNI).  Use of short and long -acting nitrates is 
permitted.  
Medications  specifically prohibited in the exclusion criteria are not allowed  for concomitant 
use with study intervention . In particular,  the following are prohibit ed: 
• Use of IV diuretic or inotropes  
• PDE5i such as vardenafil, tadalafil, and sildenafil  
• sGC stimulators (e.g., r iociguat or vericiguat ) 
If there is a clinical indication for any medications  specifically prohibited, di scontinuation 
from study intervention may be required. This would result in not meeting criteria for the 
primary endpoint treatment  tolerability . The investigator should discuss any questions 
regarding this with the medical monitor . The final decision on any medical  therapy  rests with 
the investigator and/or the participant ’s primary physician. However, the decision to continue 
the participant on study intervention  requires the mutual agreement of the investigator and the 
participant  and the information of  the Sponsor . 
The medical monitor  should be contacted if there are any questions regarding concomitant or 
prior therapy.  
6.9.1 Rescue Medicine  
No rescue or supportive medications are specified for use in this study.  
7. Discontinuation of Study Intervention and Part icipant 
Discontinuation/Withdrawal  
Discontinuation of specific sites or of the study as a whole are detailed in Section  10.1. 
7.1 Discontinuation of S tudy Intervention  
Discontinuation is defined as the inability to complete treatment between V isit 1 and V isit 2. 
One missing/ forgotten dose is permitted . All cases exceeding one missing dose  will not be 
counted for the analysis  of the primary endpoint.  
Participants may discontinue study intervention or be d iscontinued from the study at the 
discretion of the investigator should any untoward effect occur.  In addition, a participant may 
be discontinued from study intervention by the investigator or the Spon sor if study 
intervention is inappropriate, the study plan is violated, or for administrative and/or other 
safety reasons.  If study intervention is permanently discontinued, the participant should 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   24 of 44 
 
remain in the study to be evaluated at Visit 2 (Day 14). Discontinuation of study intervention 
does not represent withdrawal from the study.  
A participant must be discontinued from study intervention , but continue to be monitored in 
the study for any of the following reasons:  
• The participant experiences symptomati c hypotension  of moderate to severe intensity  
(Section 10.3.3 ) during the treatment period .  
• The participant or participant’s legally acceptable representative requests to 
discontinue study intervention.  
• The participant has a medical condition or personal circumstance, which in the opinion 
of the investigator and/or Sponsor, placed the participant at unnecessary risk from 
continued administration of study interve ntion.  
• The participant has a confirmed positive serum pregnancy test.  
7.1.1 Temporary Interruption   
Temporary i nterruption of study intervention is permitted at any time during the study at the 
investigator’s discretion .  
7.1.2 Rechallenge  
Upon temporary interruption of the study intervention,  resumption of treatment at 5 mg is 
allowed if the interruption was not related  to symptomatic hypotension  of moderate to severe 
intensity . Intake should be resumed as soon as medically acceptable at th e discretion of the 
investigator. In all cases, the reason for study intervention interruption must be recorded in the 
eCRF and the participant’s medical records.  
7.2 Participant Discontinuation/Withdrawal from the Study  
• A participant may withdraw from the st udy at any time at the participant’s  own 
request, for any reason (or without providing any reason).  
• A participant  may be withdrawn at any time at the discretion of the investigator for 
safety,  behavioral, or compliance  reasons.   
• At the time of discontinui ng from the study, if possible, an unscheduled  visit should be 
conducted, as shown in the SoA. See SoA for the data to be collected at the time of 
study discontinuation and follow -up and for any further evaluations that need to be 
completed.  
• The participant will be permanently discontinued from the study intervention and the 
study at that time.  
• If the participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any data collected before such a with drawal of consent.  
7.3 Lost to Follow Up  
A participant will be considered lost to follow -up if the participant  fails to return for Visit 2  
and is unable to be contacted by the study site.  
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   25 of 44 
 
• The site must attempt to contact the participant and reschedule the missed visit as soon 
as possible , counsel the participant on the importance of maintaining the assigned visit 
schedule , and ascertain whether the par ticipant wishes to and/or should continue in the 
study.  
• Before a participant is deemed lost to follow up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone 
calls, and if necessary, a cer tified letter to the participant’s last known mailing address 
or local equivalent methods). These contact attempts should be documented in the 
participant’s medical record.  
• Should the participant continue to be unreachable, the participant  will be consider ed 
lost to follow up . 
8. Study Assessments and Procedures  
• Study procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.  
• Adherence to the study design requirements, including those specified in the SoA, is 
essenti al and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management ( e.g., 
local laboratory ) and obtained before signing of the ICF may be utilized for screening 
or baseline purposes provided the procedures met the protocol -specified criteria and 
were performed within the timeframe defined in the SoA.   
• In the event of a significant study -continuity issue ( e.g. caused by a pandemic), 
alternate strategies for partici pant visits, assessments, medication distribution and 
monitoring may be implemented by the sponsor or the investigator, as per local health 
authority/ethics requirements.  
8.1 Administrative and Baseline  Procedures  
Administrative and baseline procedures are summarized in the SoA ( Section 1.3). 
8.2 Efficacy  Assessments  
There are no  efficacy  assessments in this study . 
8.3 Safety Assessments  
Planned timepoints for all safety as sessments are provided in the SoA  (Section 1.3). 
Participants will be assessed to determine tolerability as described in  Section 9.3.2 .  
8.3.1 Physical Examinations  
• A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory, gastrointestinal and neurological  systems. Height and 
weight  will also be measured and recorded.  
• Investigators  should pay special attention to clinical signs related to previous serious 
illnesses.  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   26 of 44 
 
8.3.2 Vital Signs  
Skin temperature, and respiratory rate  will be recorded  at screening . 
BP and pulse rate will be assessed at the timepoin ts defined in Section 1.3. Measurements will 
be done in triplicate , and the average value will be recorded in the CRF.  
Accurate measurement of BP is e ssential to assess tolerability and to detect potential safety 
signals during the study. Several factors related to the participant can cause significant 
deviations in measured BP. These include room temperature, exercise, alcohol or nicotine 
consumption, positioning of the arm, muscle tension, bladder distension, talking, and 
background noise.  
• No other procedures may be performed during the BP and pulse rate measurements.  
• The participant should be asked to remove all clothing that covers the location of cu ff 
placement.  
• BP and pulse rate measurements should be preceded by at least 10 minutes of rest with 
the participant comfortably seated in a chair with the legs uncrossed and the back and 
arm supported in a quiet setting without distractions. Measurements should not be 
made while the participant is on an examining table. The participant should be 
instructed to relax as much as possible and to not talk during the measurement 
procedure.  
• BP and pulse rate measurements will be assessed with the participant in a  seated 
position with a completely automated device. Manual techniques will be used only if 
an automated device is not available. Whenever possible, BP measurements should be 
obtained using the same arm, same BP monitoring device, and same examiner at each  
visit.  
• The examiner should ensure that the middle of the cuff on the upper arm is at the level 
of the right atrium (the midpoint of the sternum).  
• 3 consecutive BP measurements will be recorded at intervals of approximately 2 
minutes apart. Record the time , positioning, and arm used for each measurement.  
• Assessment  of pulse rate can be manual (rather than using an automated device). 
When performed manually, pulse rate must be measured in the brachial/radial artery 
for at least 30 seconds.  
8.3.3 Electrocardiograms  
Single 12 -lead ECG will be obtained at screening visit as outlined in the SoA and reviewed by 
an investigator or medically qualified designee (consistent with local requirements) using an 
ECG machine that automatically calculates the heart rate  and measur es pulse rate , QRS, QT, 
and QTc intervals , estimated by formulas Bazett - QTcB - and Fridericia – QTcF calculated 
by data management in the eCRF.  
Participant s will refrain from nicotine -containing products and/or ingesting caffeine for at 
least 30  minutes preceding the procedure.  
12-lead ECGs should be performed after the participant  has rested quietly for approximately 
10 minutes.  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   27 of 44 
 
8.3.4 Clinical Safety Laboratory Tests  
There are no clinical laboratory tests planned during this study , with the exception of the 
following:  
1. select clinical labs in the event  that historical values are not available at screening  
2. serum pregnancy tests  in the event of an ambiguous urine result  at Visit 1  
See Section 10.2 for details . 
8.3.5 Pregnancy Testing  
• Pregnancy testing (urine or serum as required by local regulations)  should be 
conducted at Visit 1 .  
• Additional serum or urine pregnancy tests may be performed,  as determined necessary 
by the investigator or required by local regulation, to establish the absence of 
pregnancy at any time during the subject's participation in the study.  
NOTE:  If a urine test cannot be confirmed as negative ( e.g. an ambiguous result ), a serum 
pregnancy test is required .  
8.4 Adverse Events (AEs) , Serious Adverse Events  (SAEs) and Other Safety 
Reporting  
The definitions of adverse events (AEs) and serious adverse events (SAEs) can be found in 
Section 10.3. 
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain resp onsible for 
following up all AEs (see Section 7). This includes events reported by the participant (or, 
when appropriate, by a caregiver, surrogate , or the participant’s legally authorized 
representative).  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3. 
8.4.1 Time Period and Frequency for Collecting AE and SAE Information  
(S)AEs will be collected from the  start of study intervention until the end-of-study visit (Visit 
2) at the timepoints specified in the SoA (Section 1.3). (S)AEs which are related to protocol -
required study procedures ( e.g., (S)AE related to invasi ve study procedures or adjustment of 
therapy to comply with in clusion  or exclusion criteria of the study) will be recorded as 
(S)AEs from the signing of the ICF.  
Any medical occurrences /conditions  that begin in the period between signing  ICF and the 
start of study intervention , and which are not related  to a protocol -required study procedure,  
will be recorded as medical history/ current medical conditions , not as AEs.  
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance  should this exceed 24 hours  of learning of the event , as indicated in 
Section  10.3. The investigator will submit any updated SAE data to the sponsor within 24 
hours of it being available.  
Investigators are not obligated to actively seek information on AEs or SAE s after conclusion 
of the study partic ipation. However, if the investigator learns of any SAE, including a death, 
at any time after a participant has been discharged from the study, and the investigator 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   28 of 44 
 
considers the event to be reasonably related to vericiguat , the investigator must promptly 
notify the sponsor . 
8.4.2 Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
8.4.3 Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs, and AEs of special interest (as defined in 
Section 8.4.6 ), will be followed until resolution, stabilization, the event is otherwise 
explained, or the participant is lost to follow -up (as defined in Section 7.3). Further 
information on follow -up procedures is provided  in Section 10.3.  
8.4.4 Regulatory Reporting Requirements for SAEs  
• Prompt notification by the investigator to the sponsor of a n SAE is essential so that 
legal obligations and ethical responsibilities towards the safety of participants and the 
safety of a study intervention und er clinical investigation are met.  
• The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies  about the safety of a study intervention under clinical 
investigation. The sponsor will comply with count ry-specific regulatory requirements 
relating to safety reporting to the regulatory authority, institutional review boards 
(IRB s)/independent ethics committees (IEC s), and investigators.  
• An investigator who receives an investigator safety report describing an SAE or other 
specific safety information ( e.g., summary or listing of SAEs) from the sponsor will 
review and then file it along with the investigator’s brochure  and will notify the 
IRB/IEC, if appropriate according to local requirements.  
• For all studies  except those using medical devices , investigator  safety reports must be 
prepared for suspected unexpected serious adverse reactions (SUSAR s) according to 
local regulatory requirements and sponsor policy and forwarded to investigators as 
necessary.  
8.4.5 Pregnan cy 
• Details of all pregnancies in female participants will be collected after the start of 
study intervention . The time period for reporting pregnancies should align with the 
time period for post -intervention  contraception determined in Section 5.1. 
• If a pregnancy is reported, the investigator will record pregnancy inform ation on the 
appropriate form and submit it to  the sponsor within 24 hours of learning of the female 
participant pregnancy.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SA E. 
• Abnormal pregnancy outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs , and will be reported as 
such. 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   29 of 44 
 
• The participant will be followed to determine the outcome of the pregnancy. The  
investigator will collect follow -up information on the participant and the neonate and 
the information will be forwarded to the sponsor.  
• Any post -study pregnancy -related SAE considered reasonably related to the study 
intervention by the investigator will be reported to the sponsor as described in 
Section  8.4.4 . While the investigator is not obligated to actively seek this information 
in former study participants, he or she may learn of an SAE through spontaneous 
reporting.  
• Any female participant who becomes pregnant while participating in the study will  
discontinue study intervention or be withdrawn from the study . 
8.4.6 Adverse Events of Special Interest  
Symptomatic hypotension is an AESI as assessed by the investigator . 
8.5 Pharmacokinetics  
Pharmacokinetics  are not evaluated in this study . 
8.6 Pharmacodynamics  
Pharmacodynamics are not evaluated in this study.  
8.7 Genetics  
Genetics are not evaluated in this study.  
8.8 Biomarkers  
Biomarkers are not evaluated in this study.  
8.9 Immunogenicity Assessments  
There are no immunogenicity assessments planned in this study . 
8.10 Medical Resource Utilization and Health Economics  
Medical resource utilization  and health economics  parameters are not evaluated in this study.  
9. Statistical Considerations  
A statistical analysis plan will be prepared and will  include a more technical and detailed 
description of the statistical analyses described in this section.  This section is a summary of 
the planned statistical analyses of the most important endpoints including primary and  
secondary endpoints.  The analysis and reporting will be done on all data from all participants 
at the time the study ends.  
9.1 Statistical Hypotheses  
The analyses presented here will be descriptive in nature and thus no statistical hypothesis 
tests will be performed.   
9.1.1 Multiplicity Adjustment  
There will be no multiplicity adjustment performed as it is not applicable to this study.  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   30 of 44 
 
9.2 Analysis Sets 
For the purposes of analysis, the following analysis set is defined:  
Participant Analysis Set  Description  
Safety analysis set  (SAF)  • All participants assigned to investigational intervention who 
were exposed to study intervention at least once.  
9.3 Statistical  Analyses  
9.3.1 General Considerations  
No hypothesis testing will be performed. Instead, given the nature of the trial, descriptive 
statistics will be provided for data collected. All analyses will be performed on the  safety 
analysis set (SAF).  
9.3.2 Primary Endpoint  Analysis  
9.3.2.1  Definition of Endpoint(s) .  
The primary endpoint of tolerability will be  defined as the completion of  the two -week 5 mg 
dose without discontinuation  of study intervention and without symptomatic hypotension  of 
moderate to severe  intensity  (Section 10.3.3 ) between Visit 1 and Visit 2.  Participants with  
discontinuation  of study intervention (described in Section 7.1) or symptomatic hypotension 
of moderate to severe intensity would not meet criteria for the primary endpoint of treatment 
tolerability.  
9.3.2.2  Main Analytical Approach  
Participants who meet the criteria for  tolerability as defined in Section 9.3.2.1  will be 
considered for the numerator in the proportion of participants reaching tolerability. The 
denom inator will contain all participants who were included in the SAF . Thus in the case of 
100 participants  included in the SAF , all 100 will be included  as part of the denominator and 
the numerator will only include the number of participants who completed the two week 5 mg 
dose without any study intervention discontinuation and without symptomatic hypotension  of 
moderate to severe intensity . There will be no imputation of missing data. A similar approach 
will be taken for the derivation of the  proportion for the secondary endpoint analyses.  
9.3.2.3  Sensitivity Analyses  
Additional proportions will be derived as sensitivity analyses. These analyses will be 
described in detail in the statistical analysis plan.   
9.3.2.4  Supplementary Analyses  
There will be no su pplementary analyses.  
9.3.3 Secondary Endpoints  Analysis   
Analysis of s econdary endpoints will include  tabulation of  the following  using descriptive 
statistics : 
• Any AE reported between Visit 1 and Visit 2   
• Proportion  of participants who did not have an AE relat ed to study intervention 
between Visit 1 and Visit 2  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   31 of 44 
 
• Proportion  of participants who took study intervention continuously between Visit 1 
and Visit 2 or were able to restart of study intervention after any temporary 
interruption   
9.4 Interim Analysis  
No interim  analysis is planned.   
Due to the nature of this study, participant -level treatment assignment information is available 
during study conduct.  
However, manual interim calculations of tolerability rates will not be done in order to protect 
the integrity of the study.  
9.5 Sample Size Determination  
Based on the  evidence  of a strong safety profile of vericiguat and the  
, the sample size of approximately 100 participants is considered  appropriate 
to assess the tolerability of the 5 mg initiation dose for vericiguat.  
10. Supporting Documentation and Operational Considerations  
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  
10.1.1  Regulatory and Ethical Considerations  
 
• This study will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) international ethical 
guidelines  
• Applicable ICH Good Cl inical Practice (GCP) guidelines  
• Applicable laws and regulations  
• The protocol, protocol amendments, ICF, investigator ’s brochure, and other relevant 
documents ( e.g., advertisements) must be submitted , reviewed and approved in 
accordance with national legislation and undergo scientific and ethical assessment 
before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes  necessary to 
eliminate an immediate hazard to study participants. Any substantial modification of 
the protocol will be submitted to the competent authorities as substantial amendments 
for approval, in accordance with ICH Good Clinical Practice and nationa l and 
international regulations.  
• Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate 
hazard to study participants.  
• The investigator will be responsible for the following, as applicable : 
• Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, 
and procedures established by the IRB/IEC  
CCI
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   32 of 44 
 
• Notifying the IRB/IE C of SAEs or other significant safety findings as 
required by IRB/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements of  ICH guidelines, the IRB/IEC, and all other applicable local 
regulations  
10.1.2  Financial Disclosure  
Investigators and sub -investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate re gulatory authorities. Investigators 
are responsible for providing information on financial interests during the course of the study 
and for 1 year after completion of the study.  
10.1.3  Informed Consent Process  
• The investigator or the investigator’s representative  will explain the nature of the 
study, including the risks and benefits, to the potential participants  or their legally 
authorized representative and answer all questions regarding the study.  
• Potential participants must be informed that their participatio n is voluntary. 
Participants  or their legally authorized representatives will be required to sign a 
statement of informed consent that meets the requirements of 21 CFR 50, local 
regulations, ICH guidelines, Health Insurance Portability and Accountability A ct 
(HIPAA), where applicable, and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The autho rized person obtaining the informed consent must also 
sign the ICF.  
• Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study.  
• A copy of the ICF(s) must be provided to the participants  or their legally authorized 
representative.   
• Participants who are rescreened are required to sign a new ICF  
10.1.4  Recruitment Strategy  
Detailed description of the recruitment strategy will be provided in country -specific 
documentation as required.  
10.1.5  Data Protection  
• Partici pants will be assigned a unique identifier by the sponsor. Any participant 
records , datasets  or biological samples  that are transferred to the sponsor will contain 
the identifier only; participant names or any information which would make the 
participant i dentifiable will not be transferred.  
• Participant s must be informed that their personal study -related data will be used by the 
sponsor in accordance with local data protection law. The level of disclosure must also 
be explained to the participant  who will be required to give consent for their data to be 
used as described in the informed consent .  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   33 of 44 
 
• Participants  must be informed that their medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed b y the sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.  
• The contract between sponsor and study sites specifies responsibilities of the parties 
related data protection, including handling of data security breaches and r espective 
communication and cooperation of the parties.  
• Information technology systems used to collect, process, and store study -related data 
are secured by technical and organizational security measures designed to protect such 
data against accidental or unlawful loss, alteration, or unauthorized disclosure or 
access.  
10.1.6  Committees Structure  
Steering Committee   
The Steering Committee, which consists of external experts in the area of heart failure , will 
ensure the overarching integrity of the study, including : 
• Consultation on study -related activities, including guidance and support on study 
enrol lment  
• Provision of recommendations regarding amendments to the protocol  
• Contribution to and oversight of publications and communication of study results  
• Participant safety : this will be continuously monitored by the Steering Committee and 
the sponsor, and include safety signal detection at any time during the study  
• All safety data collected will be summarized and reviewed by the Steering Committee  
and the sponsor for agreement of next steps.  
10.1.7  Dissemination of Clinical Study Data  
Bayer fulfills its commitment to publicly disclose study results through posting the result of 
its studies on public registries in accordance with applicable law and regulations.  
Result Summarie s of Bayer's sponsored clinical studies in drug development Phases 2, 3 and 
4 and Phase 1 studies in patients are provided in the Bayer Trial s Explorer  application after 
marketing authorization approval in line with the position of the global pharmaceutica l 
industry associations laid down in the "Joint Position on the Disclosure of Clinical Trial 
Information via Clinical Trial Registries and Databases". In addition , results of clinical drug 
trials will be provided on the publicly funded website s, ClinicalTr ials.gov , and EU Clinical 
Trials Information System (CTIS) in line with the applicable regulations.  
In accordance with the current EU regulation s, result summaries will be submitted within one 
year from the end of the study in all participating countries for studies in adult populations , or 
within 6 months from the Last Patient Last Visit (LPLV) date for studies in pediatric 
populations . No preliminary data analysis based on regional requirements (e.g., on EU data 
only) will be performed, as this might comp romise data integrity and the scientific validity of 
the study. Bayer commits to sharing upon request from qualified scientific and medical 
researchers patient -level clinical trial data, study -level clinical trial data, and protocols from 
clinical trials i n patients for medicines and indications approved in the United States and 
European Union (EU) on or after January 01, 2014 as necessary for conducting legitimate 
research.  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   34 of 44 
 
All Bayer -sponsored clinical trials are considered for publication in scientific li terature , 
irrespective of whether the results of the clinical trials are positive or negative.  
10.1.8  Data Quality Assurance  
• All participant data relating to the study will be recorded on printed or electronic 
CRF s unless transmitted to the sponsor or designee electronically ( e.g., laboratory 
data). The investigator is responsible for verifying that data entries are accurate and 
correct by physically or electronically signing the CRF.  
• Guidance on completion of CRFs  will be provided in  CRF Completion Guidelines  
• The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source documents.  
• QTLs will be predefined in the integrated data review plan to identify systematic 
issues that can impact participant safety and/or reliability of study results. These 
predefined parameters will be monitored during the study and important deviations 
from the QTLs and remedial actions taken will be summa rized in the clinical study 
report.  
• Monitoring details describing strategy , including definition of study critical data items 
and processes  (e.g., risk-based initiatives in operations and quality such as risk 
management and mitigation strategies and analytical risk-based monitoring), methods, 
responsibilities and requirements, including handling of noncompliance issues and  
monitoring techniques (central, remote, or on -site monitoring) are provided in the  
monitoring plan. 
• The sponsor or designee is responsi ble for the data management of this study 
including quality checking of the data.  
• The sponsor assumes accountability for actions delegated to other individuals ( e.g., 
contract research organizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by the investigator for 15 years after study completion unless local 
regulations or institutional policies require a longer retention period. No records may 
be destroyed during the retention period without the written approval of the sponsor. 
No records may be transferred to another location or party without written notification 
to the sponsor.  
10.1.9  Source Documents  
• Source documents provide evidence for the ex istence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the s ource documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available.  
• Definition of what constitutes source data and its origin can be found in  the Source 
Data Location List  
• The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
• The sponsor  or designee  will perform monitoring to confirm that data entered  into the 
CRF by authorized site personnel are accurate, complete, and verifiable from source 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   35 of 44 
 
documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protoco l and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
10.1.10  Study and Site Start and Closure  
Study Start  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
The start of a c linical study in the EU  is defined as the date on which the first site is declared 
by the sponsor to be ready to enroll in a country  and clinical study will be open for 
recruitment of participants .  
Study/Site Termination  
The sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the ear ly closure of a study site by the sponsor or investigator may include but are 
not limited to:  
For study termination:  
• Discontinuation of further study intervention development  
For site termination:  
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  
• Inadequate  or no  recruitment  (evaluated after a reas onable amount of time)  of 
participants by the investigator  
• Total number of participants included ea rlier than expected.  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators , the IECs/IRBs, the regulatory authorities, and any contract research 
organization(s) used in the study of the reason for terminat ion or suspension, as specified by 
the applicable regulatory requirements. The investigator shall promptly inform the participant 
and should assure appropriate participant therapy and/or follow -up. 
 
10.1.11  Publication Policy  
• The results of this study may be publi shed or presented at scientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor 
before submission. This allows the sponsor to protect proprietary information and to 
provide comments.  
• The sponsor  will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   36 of 44 
 
site data. I n this case, a coordinating investigator will be designated by mutual 
agreement.  
• Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.  
 
10.2 Appendix 2: Clinical Laboratory  Tests  
• The tests detailed in Table 10-1 may be performed  by the local laboratory.   
• Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol . 
• Additional tests may be perfor med at any time during the study as determined 
necessary by the investigator or required by local regulations.  
Table 10-1: Protocol -required Safety Laboratory Tests  
Laboratory 
Tests  Parameters  
Pregnancy 
testing  • Highly sensitive  urine hCG pregnancy test (as needed for women of 
childbearing potential)  
Clinical 
Chemistry  • eGFR, albumin, total bilirubin, , ALT and AST  (as needed  for screening  if 
not available based on routine measurements  [see Section 1.3]) 
Hematology  • Hemoglobin  
ALT = alanine aminotransferase, AST = aspartate aminotransferase, eGFR = estimated 
glomerular filtration rate , HCG = human chorionic gonadotropin  
NOTES:  
Local urine pregnancy testing will be standard for the protocol unless serum testing is required by 
local regulation or IRB/IEC  
eGFR, albumin, hemoglobin, total bilirubin, ALT and AST values must be available at screening. Values 
obtain ed as part of routine management should be used if measured within 30 days prior to Visit 1 . If 
data is unavailable, values should be determined using a local lab.  
Investigators must document their review of each laboratory safety report.  
10.3 Appendix 3: AEs and SAEs : Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  
10.3.1  Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, associated 
with the use of study intervention, whether or not considered related to the study 
intervention.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) associated 
with the use of study intervention.  
Events Meetin g the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically  significant in the 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   37 of 44 
 
medical and scientific judgment of the investigator (i.e., not related to progression of 
underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of  the condition.  
• New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.  
• Signs, symptoms , or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overd oses should be reported regardless of sequelae.  
• Sign, symptoms, or the clinical sequelae of suspected medication errors, misuse and 
abuse of either study intervention or a concomitant medication. Medication errors, 
misuse and abuse per se will not be repor ted as an AE/SAE, unless it is resulting in 
AE/SAE. Such medication errors, misuse and abuse should be reported regardless of 
sequelae . 
Events NOT  Meeting the AE Definition  
• Any abnormal laboratory findings or other abnormal safety assessments that are 
associated with the underlying disease, unless judged by the investigator to be more 
severe than expected for the participant’s condition  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE  
• Situations in which an untoward medical occurrence did not occur (social and /or 
convenience admission to a hospital)  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen  
 
10.3.2  Definition of SAE  
An SAE is defined as any untoward medical occurrence  that, at any dose, meets the one or 
more of the criteria listed:  
a. Results in death  
b. Is life threatening  
• The term life threatening  in the definition of serious  refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
c. Requires inpatient hospitalization or prolongation of existing hospitalization  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   38 of 44 
 
• In general, hospitalization signifies that the participant has been admitted (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physi cian’s office or 
outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether hospitalization occurred or w as necessary, the 
AE should be considered serious.  
• Hospitalization for elective treatment of a pre -existing condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e.g., sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Other situations:  
• Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations such as significant medical 
events that  that may not be immediately life -threatening or result in death or 
hospitalization but  may jeopardize the participant or may re quire medical or surgical 
intervention to prevent one of the other outcomes listed in the above definition. These 
events should usually be considered serious.  
o Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergenc y room or at home for allergic bronchospasm , blood 
dyscrasias, convulsions, or development of intervention dependency or 
intervention abuse.  
10.3.3  Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of th e investigator to review all 
documentation (e.g., hospital progress notes, laboratory reports, and diagnostics 
reports) related to the event.  
• The investigator will then record all relevant AE/SAE information.  
• It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to the sponsor  in lieu of completion of the required form.  
• There may be instances when copies of medical records for certain cases are requested 
by the spons or. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submission to the sponsor . 
• The investigator will attempt to establish a diagnosis of the event based o n signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE.  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   39 of 44 
 
Assessment of Intensity  
• The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to one of the following categories:  
• Mild: A type of adverse event that is usually transient and may require only 
minimal treatment or therapeutic intervention. The event does not generally 
interfere with usual activ ities of daily living . 
• Moderate: A type of adverse event that is usually alleviated with additional 
specific therapeutic intervention. The event interferes with usual activities of daily 
living, causing discomfort but poses no significant or permanent risk  of harm to 
the research participant.    
• Severe: A type of adverse event that interrupts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic 
intervention .   
Assessment of Causality  
• The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE. The investigator will use clinical judgment to 
determine the relationship . 
• A reasonable possibility  of a relationship conveys that there are  facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out. 
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the  event to study intervention 
administration will be considered and investigated.  
• For causality assessment, the investigator will also consult the investigator’s brochure  
and/or product information, for marketed products . 
• The investigator must review and pr ovide an assessment of causality for each AE/SAE 
and document this in the medical notes . There may be situations in which an SAE has 
occurred and the investigator has minimal information to include in the initial report to 
the sponsor . However, it is very important that the investigator always make an 
assessment of causality for every event before the initial transmission  of the SAE 
data to the sponsor . 
• The investigator may change his/her opinion of causality in light of follow -up 
information and send an SA E follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
Follow -up of AEs and SAEs  
• The investigator is obligated to perform or arrange for the conduct  of supplemental 
measurements and/or evaluations as medically indicated or as requested by the 
sponsor  to elucidate the nature and/or causality of the AE or SAE as fully as possible. 
This may include additional laboratory tests or investigations, histopath ological 
examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow -up 
period, the investigator will provide the sponsor  with a copy of any postmortem 
findings i ncluding histopathology , if available . 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   40 of 44 
 
• New or updated information will be recorded in the originally submitted documents.  
• The investigator will submit any updated SAE data to the sponso r within 24 hours of 
receipt of the information.  
 
10.3.4  Reporting of SAEs  
SAE  Reporting to the sponsor  via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to the sponsor  will be the electronic 
data collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
transmission (see next section) to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• After the study is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see next 
section) or to the medical monitor by telephone.  
• Contacts for SAE reporting can be found in Investigator Site File . 
SAE Reporting to the Sponsor  via Paper Data Collection Tool  
• Email transmission of the SAE paper data collection tool is the preferred method to 
transmit this information to the sponsor . 
• In rare circumstances and if email transmission is not feasible, notification by 
telephone is acceptable with a copy of the SAE da ta collection tool sent by overnight 
mail or courier service.  
• Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE data collection tool within the designated reporting 
timeframes.  
• Contacts for SAE r eporting can be found in the Investigator Site File . 
10.4 Appendix 4: Contraceptive and Barrier Guidance  
10.4.1  Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanently sterile (see below).  
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   41 of 44 
 
Women in the following categories are considered WOCBP  (fertile)  
1. Following menarch e 
2. From the time of menarche until becoming p ostmenopausal unless permanently sterile (see 
below) : 
• A postmenopausal state is defined as no menses for 12 m onths without an alternative 
medical cause.  
• A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using 
hormonal contraception or hormonal replacement therapy (HRT). 
However, in the absence of 12 months of amenorrhea, confirmation with 
more than one FSH measurement > 40 mIU/mL  (for United States only: 
FSH levels > 40 mIU/mL and estradiol < 20 pg/mL)  is required.  
• Females on HRT and whose menopausal status is in doubt will be re quired 
to use one of the non -estrogen hormonal highly effective contraception 
methods if they wish to continue their HRT during the study. Otherwise, 
they must discontinue HRT to allow confirmation of postmenopausal status 
before study enrollment.  
• Permanent sterilization methods (for the purpose of this study) include:  
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophorectomy  
• For individuals with permanent infertility due to an alternate medical cause 
other than th e above, ( e.g., Mullerian agenesis, androgen insensitivity, 
gonadal dysgenesis), investigator discretion should be applied to 
determining study entry.  
Note : Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.  
If fertility is unclear ( e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered.  
Woman of  Nonchildbearing Potential (WONCBP)  
Women in the following categories are considered WONCBP:  
1. Premenopausal female with permanent infertility due to one of the following:  
a) Documented hysterectomy  
b) Documented bilateral salpingectomy  
c) Documented bilateral oophor ectomy  
d) For individuals with permanent infertility due to an alternate medical cause other 
than the above,  (e.g., Mullerian agenesis, androgen insensitivity, gonadal 
dysgenesis), investigator discretion should be applied to determining study entry.  
Note : Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview . 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   42 of 44 
 
2. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical  cause.  
• A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using 
hormonal contraception or hormonal replacement therapy (HRT). 
However, in the absence of 12 months of ameno rrhea, confirmation with 
more than one FSH measurement >40 mIU/mL  (for United States only: 
FSH levels >40 mIU/mL and estradiol <20pg/mL)  is required.   
• Females on HRT and whose menopausal status is in doubt must 
discontinue HRT to allow confirmation of pos tmenopausal status before 
study enrollment.  
 
10.4.2  Contraception Guidance  
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency Failure rate of <  1% per year when used 
consistently and correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulationc 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)c 
• Bilateral tubal occlusion  
• Azoospermic partner (vasectomized or due to a medical cause)  
Azoospermia is  a highly effective contraceptive method provided that the partner is the sole sexual partner 
of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used.  Spermatogenesis cycle is approximately 90 days.  
Note: documentation of azoospermia for a male participant can come from the site personnel’s review of 
the participant’s medical records, medical examination, or medical history interview.  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in re lation to the duration of the study and the preferred and usual 
lifestyle of the participant.  
a) Contraceptive use by men or women should be consistent with local regulations regarding the use of 
contraceptive methods for those participating in clinical studies.  
b) Failure rate of <  1% per year when used consistently and correctly. Typical use failure rates differ from 
those when used consistently and correctly.  
c) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines , acceptable 
contraceptive methods are limited to those which inhibit ovulation as the primary mode of action.  
Note: Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational a menorrhea method (LAM) are not acceptable methods of contraception  for 
this study .  Male condom and female condom should not be used together (due to risk of failure from 
friction).  
 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   43 of 44 
 
11. References  
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et 
al. Vericiguat in Patients with Heart Failure and Reduced Ejection 
Fraction. N Engl J Med. 2020 May;382(20):1883 -93. 
Boettcher M, Thomas D, Mueck W, Loewen S, Arens E, Yoshikawa K, et al. 
Safety, pharmacodynamic, and  pharmacokinetic characterization of 
vericiguat: results from six phase I studies in healthy subjects. Eur J Clin 
Pharmacol. 2021 Apr;77(4):527 -37. 
Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et 
al. Riociguat for the treatment of ch ronic thromboembolic pulmonary 
hypertension. N Engl J Med. 2013a Jul 25;369(4):319 -29. 
Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. 
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J 
Med. 2013b Jul;369(4):3 30-40. 
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: 
A Report of the American College of Cardiology/American Heart 
Association Joint Committee on Clinical Practic e Guidelines. Circulation. 
2022 Apr 1:101161CIR0000000000001063.  
Kerwagen F, Ohlmeier C, Evers T, Herrmann S, Bayh I, Michel A, et al. 
Indicators of adherence and persistence to vericiguat in Germany: a 
prescription claims data analysis. DGK Herztage, Bonn . Clin Res Cardiol. 
2023;112:1713.  
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic 
heart failure. Eur Heart J. 2021 Sep 21;42(36):3599 -726. 
PH-38545. Population pharmacokinetic modeling of BAY 1021189 in healthy 
volunteers and virtual heart failure patients. 2015.  
PH-38550. Exploratory population pharmacokinetic / pharmacodynamics 
analysis to characterize the variability in the exposure -response 
relationship of ve riciguat (BAY 1021189) in worsening heart failure 
patients in the study 15371. (Study 17401 PH -38550, version 2.0). Bayer 
Healthcare AG. 2020.  
PH-40726. Pooled safety and PD evaluation of Phase 1 single and multiple dose 
studies with vericiguat in healthy volunteers. 2020.  
R-13340. Exposure -Response (Safety/Efficacy) Analysis of Vericiguat (MK -
1242) in Subjects With HFrEF in the Phase 3 Study VICTORIA. (Study 
20965 R -13340, version 1.0). Merck and Co., Inc. 2020.  
Victores A, Bash L, Ru X, McMullan CJ, Melar agno, Stevenson AL, et al. . 
Who? Characterizing vericiguat use in a real -world HFrEF patient 
CONFIDENTIAL  Clinical Stu dy Protocol  
No. B AY 1021189  / 216 83 
29 NOV 2023   Page:   44 of 44 
 
population. Abstract: 23 -A-12830 -ACC (American College of Cardiology 
Conference, March 4 – 6, 2023, New Orleans, US). 2023.  
 